Adamas Pharmaceuticals Expands Clinical Trial for Treatment of Levodopa-induced Dyskinesia

(October 29, 2014) - Adamas Pharmaceuticals, Inc. announced that it has initiated an additional Phase 3 safety and efficacy study evaluating ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. ADS-5102, an investigational agent, is a high dose, controlled-release version of amantadine HCl administered once daily at bedtime. Read more…

Click for a printer friendly version